Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE-ATTAIN-ADOLESCENTS oral orforglipron versus placebo in adolescents with obesity or overweight
jRCT2051240208Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Randomised, double-blind trial in obesity and Overweight comparing Orforglipron with Placebo (2 arms). Primary endpoint: Percent change from baseline in body mass index. Started Jan 2025; status: recruiting.
02
Drugs
orforglipron
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on jRCT2051240208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240208.